At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 5 target
Drug / intervention
ARC-IM Investigational Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Support Hemodynamic Management in People With Typical and Atypical Parkinson's Disease
In Brief
A clinical study evaluating ARC-IM Investigational System for Hypotension Symptomatic and 4 related conditions. Currently recruiting, targeting 5 participants across 1 site.
Detailed Summary
The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson's Disease, who suffer from orthostatic hypotension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypotension Symptomatic, Parkinson's Disease, Orthostatic Hypotension, Dysautonomic, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
CountriesSwitzerland
Collaborators--
Timeline
N/ARecruiting
202620272028202920302031
First PostedApr 2025
Enrollment StartJul 2025
TodayJul 2026
Primary CompletionMay 2031
First PostedApr 9, 2025
Enrollment StartJul 3, 2025
Primary CompletionMay 1, 2031
TodayJul 1, 2026
Enrollment to primary: 5.8 yearsPosted 1.2 years agoPrimary completion in 4.8 years
Interventions
ARC-IM Investigational Systemdevice
Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.